AI
ATRA icon

ArchPoint Investors’s Atara Biotherapeutics ATRA Stock Holding History

ArchPoint Investors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5
Closed -$3K – 154
2015
Q4 		$3K Buy
+5
New +$3.78K ﹤0.01% 150

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Eagle Asset Management
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ArchPoint Investors's ATRA Position: Q1 2016 in Review

ArchPoint Investors sold out of Atara Biotherapeutics (ATRA) in Q1 2016, closing a stake of 5 shares — an estimated $3K sold.

ArchPoint Investors first reported a position in ATRA in Q4 2015 and held it in 1 quarter. The position peaked at $3K in Q4 2015. 71 funds tracked by Wall St. Rank hold ATRA as of Q1 2016.

  • ArchPoint Investors reported no remaining Atara Biotherapeutics position as of Q1 2016 after selling out during the quarter.
  • ArchPoint Investors sold 5 Atara Biotherapeutics shares in Q1 2016, an estimated $3K.
  • ArchPoint Investors first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 1 quarter.
  • ArchPoint Investors's Atara Biotherapeutics position peaked at $3K in Q4 2015.
  • 71 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2016.

Based on ArchPoint Investors's 13F filing for Q1 2016, filed 10 May 2016.